Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: Lausanne : Frontiers Editorial Office
    • Subject Terms:
      COVID-19*/prevention & control ; Neoplasms*; Humans ; Aged ; COVID-19 Vaccines ; Cross-Sectional Studies ; China/epidemiology
    • Abstract:
      Background: Despite the elevated COVID-19 risk for older adults with cancer, vaccine hesitancy poses a significant barrier to their immunization. Intriguingly, there is limited research on the prevalence of willingness to receive the second booster dose and associated determinants in older adults with cancer.
      Objective: Our objective was to ascertain the level of awareness about COVID-19 vaccines and to uncover the factors influencing the willingness to receive the second booster among Chinese cancer patients aged 65 years and over.
      Methods: To achieve our objective, we conducted a multicenter cross-sectional study in four tertiary hospitals from four provinces of China. This involved using a Health Belief Model (HBM) based self-administered questionnaire and medical records. Subsequently, we employed multivariable logistic regression to identify factors influencing the second COVID-19 booster vaccine willingness.
      Results: Our results showed that among 893 eligible participants, 279 (31.24%) were aged 65 years and over, and 614 (68.76%) were younger. Interestingly, the willingness to receive the second COVID-19 booster vaccine was 34.1% (95/279) (OR: 1.043, 95% CI: 0.858, 1.267) in participants aged 65 years and over, which was similar to participants aged under 65 years (34.1% vs. 35.5%, p  = 0.673). Furthermore, our findings revealed that a positive attitude toward the booster and recommendations from healthcare providers and family members were positively associated with vaccine willingness. Conversely, perceptions of negative impacts on cancer control and vaccine accessibility regarding the second COVID-19 booster were inversely related to the outcome event (all p  < 0.05).
      Conclusion: Our study concludes with the finding of a low willingness toward the second COVID-19 booster in Chinese cancer patients, particularly in the older adults, a fact which warrants attention. This reluctance raises their risk of infection and potential for severe outcomes. Consequently, we recommend using media and community outreach to dispel misconceptions, promote the booster's benefits, and encourage vaccine discussions with healthcare providers and family members.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2024 Zhang, Yang, Su, Lan, Song, Zhang and Xu.)
    • References:
      Cancer Discov. 2020 Jun;10(6):783-791. (PMID: 32345594)
      Ann Intern Med. 2020 Dec 15;173(12):964-973. (PMID: 32886525)
      Vaccines (Basel). 2022 Aug 06;10(8):. (PMID: 36016158)
      JNCI Cancer Spectr. 2021 Jun 29;5(3):Pkab049. (PMID: 34195543)
      Front Public Health. 2022 Dec 15;10:986916. (PMID: 36589991)
      BMJ. 2022 May 24;377:o1305. (PMID: 35609918)
      Drug Discov Ther. 2022;16(1):30-36. (PMID: 35264472)
      Front Med (Lausanne). 2021 Jan 14;7:560685. (PMID: 33521004)
      Vaccines (Basel). 2022 Jul 12;10(7):. (PMID: 35891277)
      BMJ. 2022 Mar 30;376:o842. (PMID: 35354586)
      EBioMedicine. 2016 Oct;12:295-301. (PMID: 27658738)
      Vaccines (Basel). 2021 Jul 16;9(7):. (PMID: 34358208)
      F1000Res. 2021 Sep 27;10:975. (PMID: 36051540)
      N Engl J Med. 2022 Jan 27;386(4):340-350. (PMID: 35021002)
      Open Forum Infect Dis. 2023 Mar 01;10(3):ofad109. (PMID: 36968954)
      China CDC Wkly. 2023 Mar 10;5(10):223-228. (PMID: 37006443)
      Lancet Infect Dis. 2022 Jul;22(7):1002-1010. (PMID: 35405090)
      Vaccines (Basel). 2023 Feb 08;11(2):. (PMID: 36851269)
      Vaccine. 2022 Nov 2;40(46):6649-6657. (PMID: 36210253)
      Influenza Other Respir Viruses. 2023 Mar 01;17(3):e13104. (PMID: 36875208)
      Eur J Cancer. 2020 Dec;141:171-184. (PMID: 33161241)
      J Med Econ. 2022 Jan-Dec;25(1):119-128. (PMID: 34989654)
      BMJ. 2022 Jul 6;378:e071502. (PMID: 35793826)
      Clin Microbiol Infect. 2022 Feb;28(2):202-221. (PMID: 34715347)
    • Contributed Indexing:
      Keywords: cancer; hesitancy; older adults; second booster of COVID-19 vaccine; vaccine willingness
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20240308 Date Completed: 20240311 Latest Revision: 20240502
    • Publication Date:
      20240503
    • Accession Number:
      PMC10917962
    • Accession Number:
      10.3389/fpubh.2024.1298070
    • Accession Number:
      38454989